MACNICA,-INC.
7.11.2016 11:02:05 CET | Business Wire | Press release
Macnica, Inc., a global leader in distributing semiconductors, electronic components, and network equipment, with its headquarter located in 1-6-3 Shin-Yokohama, Kohoku-ku, Yokohama, Japan (“Macnica”), today expanded its Mpression IP portfolio releasing SLVS-EC interface IP core for ALTERA FPGA compliant with SLVS-EC interface technology newly incorporated into Sony CMOS Image Sensor. Users can quickly develop and introduce their products early into market with SLVS-EC technology.
Macnica is a global, technology oriented distributor particularly focusing on demand creation. Macnica not only offers outstanding technical support for its product lines but also provides its original products and services under its “Mpression” brand for satisfying customer needs and solving issues.
Sony CMOS Image Sensor with SLVS-EC interface capable of high speed data
transfer will be introduced into CMOS Image Sensor market to satisfy
needs for trending higher resolution and higher framerate.
Mpression
SLVS-EC Rx IP Macnica has developed can support and contribute users who
develop advanced products supporting SLVS-EC interface.
Macnica has paid attention to SLVS-EC interface in the early days and
realized a world first solution to receive high speed image data
transmitted over SLVS-EC interface on ALTERA FPGA.
Now, the IP
enables to connect Sony high resolution and high framerate CMOS Image
Sensor to FPGA easily. It is ideal for a various applications like the
products with CMOS image sensor and FPGA to receive the image data.
Macnica is licensing the IP worldwide through its subsidiaries or
partners. ATD Electronique, an affiliate of Macnica sells and supports
it in Europe.
Macnica will exhibit demonstration of SLVS-EC Rx IP
at the booth of ATD Electronique in VISION SHOW held in Stuttgart,
Germany from November 8 to 10. Please don’t forget to visit us.
|
VISION SHOW Information |
||
| Name of Exhibition |
VISION
Leading world trade fair for machine vision |
|
| Schedule | 08 - 10 November 2016 | |
| Place | Messe Stuttgart | |
| Booth No. of ATD Electronique | Hall 1, E82 | |
* All company names and product names mentioned herein are trademarks or registered trademarks of their respective owners.
About Macnica:
Macnica has been established since 1972 as a semiconductor distribution company headquartered in Yokohama, Japan servicing customers in Japan, the Americas and Asia through its 75 sales offices around the world. Total number of employees is over 2,000 worldwide and total revenue for fiscal 2015 was approximately US$4B. Macnica is famous for having an excellent engineering team of more than 800 application engineers with strong focus on providing technical support for its customers. Macnica is continuing to improve its presence globally by having successful partners in strategic areas in the electronics market. Macnica Inc. and ATD Electronique have entered into an agreement for Macnica to acquire 49% of ATD’s outstanding shares on July 22nd, 2016.
About ATD Electronique:
ATD Electronique, who was founded in 1990 represents and distributes innovative electronic component brands and offers engineering services for machine vision and imaging applications through its offices in France and Germany and its representatives in Italy and Spain. Its product portfolio includes image sensors, controller & interface ICs, ISPs as well as development tools and design services enabling fast and efficient realization of new high performance camera systems for markets such as automotive, medical, security and machine vision.
About Mpression:
Mpression represents an integration and collection of all original
technology solutions of Macnica group such as software, platforms,
evaluation boards, and others which has been developed, provided and
supported in each country by each Macnica group companies.
Macnica
provides its advanced and ready-to-use system level solutions to
customers based on the accumulated know-hows by the very experienced
engineers from worldwide group companies, and thus leads to maximizing
the value of products as well as shortening customer's development time.
Macnica
is going to propose and support the IP offering one-stop services
through its group companies in all regions from country to country in
Europe, USA, China, and Asia.
Please visit our web-site (http://m-pression.com/
)
for a full detail of Mpression.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161107005041/en/
Contact:
Macnica, Inc.
Hajime Nakamura, 81-45-470-9838
Sales Planning,
Advanced Technology
AtdSpl@macnica.co.jp
FAX:
81-45-470-9857
Macnica Bldg No.2, 1-5-5 Shin-Yokohama, Kouhoku-ku,
Yokohama, 222-8563 JAPAN
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st
Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys20.4.2026 16:00:00 CEST | Press release
Industry’s most widely adopted PETG material meets industry-leading cleanliness, compliance, and RNase/DNase-free validation—now available across the full bioprocessing workflow. SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with SaniSure’s proprietary process and advanced automation. This launch expands SaniSure’s established PharmaTainer® platform—extending its proven cleanliness, robustness, and performance attributes to include industry-standard PETG alongside its existing PET and PC offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420641769/en/ PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bioprocessing applications. Available in volumes from 10 mL stability vials to 10 L carboys — in sterile (gamma-irradiated) an
Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 15:08:00 CEST | Press release
Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 15:00:00 CEST | Press release
– Highly innovative and original gameplay earns strong reception from players around the globe – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broade
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
